Please try another search
Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products, such as levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is headquartered in Taizhou, China.
Name | Age | Since | Title |
---|---|---|---|
Jian Hu | 44 | 2014 | Chairman |
Jin Sheng Hu | 69 | 2014 | Director |
Meng Tang | 35 | 2020 | Supervisor |
Zhifang Sun | 56 | 2020 | Director |
Lingqiao Li | 44 | 2020 | Supervisor |
Chaobo Wang | 42 | 2020 | Supervisor |
Hongfei Zhang | - | 2023 | Supervisor |
Wenwen Shen | 45 | 2017 | Independent Director |
Weiyi Shen | 43 | 2021 | Vice Chairman & GM |
Hong Fan Yang | 59 | 2017 | Independent Director |
Fangwei Zheng | - | 2023 | Chairman of the Supervisory Board |
Xin Xie | 51 | 2017 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review